Chronic Obstructive Pulmonary Disease (COPD) Management

- Update of COPD guidance based on NICE NG115 (Dec2018). This replaces NICE CG101.

- Diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally smoking or a history of smoking) presenting with exertional breathlessness, chronic cough, regular sputum production, frequent winter 'bronchitis' or wheeze.

- The fundamentals of COPD care include:
  - Offering support and treatment to stop smoking
  - Offer pulmonary rehabilitation
  - Offering pneumococcal vaccination and an annual flu vaccination
  - Co-develop a personalised self-management plan (respiratory action plan)
  - Optimise treatment for co-morbidities

All of the above should be offered before commencing pharmacological treatment and reviewed at each patient contact.

- NICE recommends commencing inhaled therapies only if all the above interventions have been offered (if appropriate) and inhaled therapies are needed to relieve breathlessness or exercise limitation or the patient has had exacerbations.

- Before stepping up treatment to the next stage in the therapeutic management of COPD, the patient’s inhaler technique, compliance with administration instructions and tolerance of the current device should be checked.

- Combination inhaled therapy with LABA/LAMA is recommended for patients who remain breathless or have exacerbations despite treatment and present with no asthmatic features or features suggestive of steroid responsiveness. (See algorithm p8 for further details).

- LABA/ICS combination inhalers are recommended for patients with asthmatic features or features suggestive of steroid responsiveness.

- NICE consider triple therapy (as a single inhaler) to be a cost-effective strategy compared to LABA/LAMA and LABA/ICS in patients who continue to exacerbate or remain breathless on dual therapies.

- Conduct a clinical review before commencing triple inhaled therapy to ensure that all non-pharmacological COPD interventions have been optimised and that acute episodes of worsening symptoms are caused by COPD exacerbations and not by other physical or mental health conditions.

- Features from the history and examinations should be used to differentiate COPD from asthma whenever possible.
### Key

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>SABA</td>
<td>Short-acting beta2 agonist</td>
</tr>
<tr>
<td>SAMA</td>
<td>Short-acting muscarinic antagonist</td>
</tr>
<tr>
<td>LABA</td>
<td>Long-acting beta2 agonist</td>
</tr>
<tr>
<td>LAMA</td>
<td>Long-acting muscarinic antagonist</td>
</tr>
<tr>
<td>ICS</td>
<td>Inhaled corticosteroid</td>
</tr>
<tr>
<td>FEV1</td>
<td>Forced expiratory volume in 1 second</td>
</tr>
<tr>
<td>FVC</td>
<td>Forced vital capacity</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
</tbody>
</table>

### Document update

<table>
<thead>
<tr>
<th>Update Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insert NICE 1.2.14 clinical review of triple therapy to p.1 as key message</td>
<td>Sept 19</td>
</tr>
<tr>
<td>Changed the order for fobumix and fostair in management flowchart to be in line</td>
<td>Oct 19</td>
</tr>
<tr>
<td>with traffic lights and removed the following words “option if COPD + Asthma</td>
<td></td>
</tr>
<tr>
<td>overlap” from the LABC/ICS box.</td>
<td></td>
</tr>
<tr>
<td>Advice on roflumilast added</td>
<td>Aug 20</td>
</tr>
</tbody>
</table>
Appendix 4: Cost comparison

Appendix 3

Appendix 2: Spirometry

Appendix 1: Inhaled corticosteroids

Managing exacerbations

Other therapies

Inhaled therapies

1. SABA or SAMA ................................................................. 10
2. LABA + LAMA combinations ........................................... 10
3. LABA + ICS combinations .............................................. 10
4. LABA + LAMA + ICS .................................................... 11

Choice of drugs/inhalers ...................................................... 11

Other therapies ................................................................. 11

Roflumilast ................................................................. 11

Oral corticosteroids ......................................................... 12

Osteoprotection ............................................................... 12

Oral prophylactic antibiotic therapy ................................... 12

Theophylline ................................................................. 13

Mucolytics ................................................................. 13

Anxiety and depression .................................................. 13

Managing exacerbations .................................................. 13

Appendix 1: Inhaled corticosteroids .................................... 14

Appendix 2: Spirometry ...................................................... 14

Appendix 3: Oxygen therapy .............................................. 15

Appendix 4: Cost comparison ............................................. 16
Definition
Chronic obstructive pulmonary disease (COPD) is a chronic slowly progressive disorder, characterised by airflow obstruction, which does not change markedly over several months. The impairment in lung function is largely fixed, but may be partially reversible by bronchodilators or other therapy. Most cases are caused by tobacco smoking, though lifelong non-smokers may develop COPD probably related to occupation.

Diagnosis
The diagnosis of COPD depends on thinking of it as a cause of breathlessness or cough. The diagnosis is suspected on the basis of symptoms and signs and is supported by spirometry.

Diagnosis of COPD should be considered for:
- Patients >35 years and
- Smokers (or significant dusty occupation) and
- patients who present with one or more of the following:
  - Exertional breathlessness
  - Chronic cough
  - Regular sputum production
  - Frequent winter ‘bronchitis’
  - wheeze

Spirometry
Spirometry is one of the essential lung function investigations in the diagnosis, severity assessment and monitoring of disease progression of COPD. It should be performed to a high standard, quality assured and only performed and interpreted by professionals assessed as competent against ARTP standards. Once certified healthcare professionals should record their qualification on National Register of certified professionals and operators which is a new framework being implemented Nationally over four years from 1st April 2017 to 31st March 2021.

Further investigations for all patients at initial diagnostic evaluation
Chest radiograph to exclude other pathologies
FBC - to identify anaemia or polycythaemia
BMI calculated
Eosinophilia

Reversibility testing
Key to an accurate diagnosis for COPD is based on signs and symptoms, supported by spirometry. Therefore in most patients, routine spirometric reversibility testing is not necessary as part of the diagnostic process or to plan initial therapy with bronchodilators or corticosteroids.

Untreated COPD and asthma are frequently distinguishable on the basis of history in people presenting for the first time. Features from the history and examinations should be used to differentiate COPD from asthma whenever possible.

Clinical features differentiating COPD and asthma

<table>
<thead>
<tr>
<th></th>
<th>COPD</th>
<th>Asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoker or ex-smoker</td>
<td>Nearly all</td>
<td>Possibly</td>
</tr>
<tr>
<td>Symptoms under age 35</td>
<td>Rare</td>
<td>Often</td>
</tr>
<tr>
<td>Chronic productive cough</td>
<td>Common</td>
<td>uncommon</td>
</tr>
<tr>
<td>Breathlessness</td>
<td>Persistent and progressive</td>
<td>Variable</td>
</tr>
<tr>
<td>Night-time waking with breathlessness and/or wheeze</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td>Significant diurnal or day-to-day variability of symptoms</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
</tbody>
</table>
To help resolve cases where diagnostic uncertainty remains, or both COPD and asthma are present use the following findings to help identify asthma:

- a large (over 400ml) response to bronchodilators
- a large (over 400ml) response to 30mg oral prednisolone daily for 2 weeks
- serial peak flow measurements showing 20% or greater diurnal or day-to-day variability

Clinically significant COPD is not present if the FEV1 and FEV1/FVC ratio return to normal with drug therapy.

**Symptoms**  
**Breathlessness**
One of the primary symptoms of COPD is breathlessness. Evaluation of breathlessness is undertaken using MRC dyspnoea scale.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Degree of breathlessness related to activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Not troubled by breathlessness except on strenuous exercise</td>
</tr>
<tr>
<td>2</td>
<td>Short of breath when hurrying or walking up a slight hill</td>
</tr>
<tr>
<td>3</td>
<td>Walks slower that contemporaries on level ground because of breathlessness, or has to stop for breath when walking at own pace</td>
</tr>
<tr>
<td>4</td>
<td>Stops for breath after walking about 100 m or after a few minutes on level ground</td>
</tr>
<tr>
<td>5</td>
<td>Too breathless to leave the house, or breathless when dressing or undressing</td>
</tr>
</tbody>
</table>


**Airflow Obstruction**
The severity of airflow obstruction is assessed according to the reduction in FEV1 as per table below

<table>
<thead>
<tr>
<th>Gradation of severity of airflow obstruction</th>
<th>Severity of airflow obstruction (NICE &amp; GOLD, 2008)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-bronchodilator FEV1/FVC</td>
<td>FEV1, % predicted</td>
</tr>
<tr>
<td>&lt;0.7</td>
<td>≥ 80%</td>
</tr>
<tr>
<td>&lt;0.7</td>
<td>50-79%</td>
</tr>
<tr>
<td>&lt;0.7</td>
<td>30 – 49%</td>
</tr>
<tr>
<td>&lt;0.7</td>
<td>&lt;30%</td>
</tr>
<tr>
<td>Stage 1 – mild</td>
<td>Stage 2 – moderate</td>
</tr>
<tr>
<td>Stage 3 – severe</td>
<td>Stage 4 – very severe</td>
</tr>
</tbody>
</table>

**Effective COPD interventions**
The following COPD interventions should be optimised before commencing pharmacological treatment and reviewed at each patient contact.

**Smoking cessation**
Smoking cessation is the single most effective intervention for reducing the risk of developing COPD and slowing its progression. For all patients with COPD

- Record an up-to-date smoking history, including pack-years smoked
- Encourage patients who smoke to stop and provide help at every opportunity

Further smoking cessation advice can be found at *live life better Derbyshire* (helpline number 0800 085 2299) or *live well derby* (helpline number 01332 641 254).
Pulmonary rehabilitation
Pulmonary rehabilitation should be made available for all patients with COPD (patients who consider themselves functionally disabled by COPD, usually MRC 3, 4 and 5 but may include patients with MRC 2) including those with recent hospitalisation for acute exacerbation, who are considered a priority to access pulmonary rehabilitation due to its impact on reducing readmission to hospital.

Patients can be referred for pulmonary rehabilitation to the following centres:

North Derbyshire
Pulmonary Rehabilitation Service, Welbeck Suite, Walton Hospital, Whitecoates Lane, Chesterfield, S40 3HW
Phone: 01246 253 067 Email: DCHST.Respiratory@nhs.net
Referral form is available through DCHS sharepoint.

South Derbyshire & Erewash
ImpACT+, London Road Community Hospital, London Road, Derby, DE1 2QY
Telephone: 01332 788225 Email: dhft.impact-plus@nhs.net
Referral form is available here or via e-Referral (service ID 7934098).

Note: If patients have excessive sputum and struggling to clear, and/or symptoms of breathlessness limiting functional activities despite on optimum inhaled medication, consider referral to respiratory physiotherapist via local respiratory teams (contact details below).

Vaccinations
Pneumococcal vaccination and annual influenza vaccination should be offered to all patients with COPD. These reduce the rates of hospital admissions and risk of death from pneumonia and influenza

Respiratory action plans (RAP)
Respiratory action plans (RAP) allow patients to adapt their lifestyles and acquire skills to successfully identify the first signs of an exacerbation and respond appropriately.
NICE recommends that patients who are at risk of exacerbation should be given a RAP that encourages them to respond promptly to the symptoms of an exacerbation. (For further details regarding management of exacerbations see p12.)

The read codes for primary care use, for the RAPs are as follows:

<table>
<thead>
<tr>
<th>Description</th>
<th>SystmOne</th>
<th>EMIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD self-management plan given</td>
<td>XaUt</td>
<td>66YI</td>
</tr>
<tr>
<td>COPD self-management plan reviewed</td>
<td>XaYZO</td>
<td>661N3</td>
</tr>
</tbody>
</table>

The local respiratory teams educate and support patient’s knowledge and understanding of their respiratory condition through provision of self-management strategies and action planning. Details of the teams are included below:

ImpACT+ - Southern Derbyshire /Erewash patients
London Road Community Hospital, London Road, Derby, DE1 2QY
Telephone: 01332 788225 Email: dhft.impact-plus@nhs.net

Community Respiratory Team - Northern Derbyshire CCG/Hardwick CCG
Walton Hospital, Chesterfield, contact number 01246 253 067
Follow-up for COPD patients in primary care
Listed in the table below is the good practice follow-up suggested by NICE for COPD patients in primary care, but annual spirometry is not included in QOF.

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Mild/Moderate/severe (stages 1 to 3)</th>
<th>Very Severe (stage 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical assessment</td>
<td>• Smoking status</td>
<td>• Smoking status</td>
</tr>
<tr>
<td></td>
<td>• Adequacy of symptom control</td>
<td>• Adequacy of symptom control</td>
</tr>
<tr>
<td></td>
<td>o Breathlessness</td>
<td>o Breathlessness</td>
</tr>
<tr>
<td></td>
<td>o Exercise tolerance</td>
<td>o Exercise tolerance</td>
</tr>
<tr>
<td></td>
<td>o Estimated exacerbation frequency</td>
<td>o Estimated exacerbation frequency</td>
</tr>
<tr>
<td></td>
<td>• Need for pulmonary rehabilitation</td>
<td>• Presence of cor pulmonale</td>
</tr>
<tr>
<td></td>
<td>• Presence of complications</td>
<td>• Need for long-term oxygen therapy</td>
</tr>
<tr>
<td></td>
<td>• Effects of each drug treatment</td>
<td>• Person with COPD nutritional state</td>
</tr>
<tr>
<td></td>
<td>• Inhaler technique</td>
<td>• Presence of depression &amp; anxiety</td>
</tr>
<tr>
<td></td>
<td>• Need for referral to specialist and therapy services.</td>
<td>• Effect of each drug treatment</td>
</tr>
<tr>
<td></td>
<td>• Presence of depression &amp; anxiety</td>
<td>• Inhaler technique</td>
</tr>
<tr>
<td></td>
<td>• Address co-morbidities including osteoporosis, other respiratory diseases and CVD.</td>
<td>• Need for social services and occupational therapy input</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Need for referral to specialist and therapy services</td>
</tr>
<tr>
<td>Measurements to make</td>
<td>• FEV\textsubscript{1} and FVC</td>
<td>• Need for pulmonary rehabilitation</td>
</tr>
<tr>
<td></td>
<td>• Calculate BMI</td>
<td>• Consider palliative care and end-of life requirements</td>
</tr>
<tr>
<td></td>
<td>• MRC dyspnoea score</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• CAT score to assess changes in symptoms and response to treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• FEV\textsubscript{1} and FVC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Calculate BMI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• MRC dyspnoea score</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CAT score to assess changes in symptoms and response to treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• SaO\textsubscript{2}</td>
</tr>
</tbody>
</table>
Management of stable COPD

Fundamentals of COPD care
- Offer treatment and support to stop smoking
- Offer pneumooccal and influenza vaccinations
- Offer pulmonary rehabilitation if indicated
- Co-develop a respiratory action plan
- Optimise treatment for co-morbidities

Check inhaler technique and compliance with particular device using In-check DIAL at annual review. If a patient is unable to use a particular device satisfactorily, then an alternative device should be sought.

Use COPD assessment tool (CAT) to assess the clinical response at baseline and when changing treatment. These treatments and plans should be revisited at every review.

Start inhaled therapy only if:
- All the above interventions have been offered (if appropriate) and
- Inhaled therapies are needed to relieve breathlessness or exercise limitation.

If exacerbations continue review as per protocol for frequent exacerbators (p9).

South – discuss patient at virtual MDT clinic or refer to ImpACT service
North – refer to the community teams

Confirm diagnosis of COPD

SABA (to use if needed)
SABA should continue through all stages of symptoms
(£1.50/device)
(£5.56/device)

**Offer LABA + LAMA (£390/pa)**
Ultibro Breezhaler, Duaklir Genuair, Anoro Ellipta, Spiolto Respimat
Choice of combination preparation should be driven by patient choice and device acceptability.

**Offer LABA + LAMA (to use if needed)**
SABA should continue through all stages of symptoms
(£1.50/device)
(£5.56/device)

**Offer LABA + LAMA**
(£390/pa)

**Patient still limited by symptoms**

Consider 3-month trial of
LAMA + LABA + ICS
(£534/pa)
In a combination inhaler

If no improvement, revert to LABA + LAMA

**Asthmatic features or features suggesting steroid responsiveness**

**Consider LABA + ICS**
Fobumix DPI (budesonide/formoterol) (£238/pa)
Or
Fostair MDI (beclometasone/formoterol 100/6) (£352/pa)

**Patient has 1 severe or 2 moderate exacerbations within a year**

**Offer**

LAMA + LABA + ICS (as a combination inhaler) Options include:
- Trimbow (Beclometasone 87mcg, Formoterol 5mcg, glycopyrronium 9 mcg) (£534/pa)
- Trelegy (Fluticasone furoate 92 mcg, Vilanterol 22 mcg, Umeclidinium 65 mcg) (£534/pa)

**Explore further options if still limited by breathlessness or subject to frequent exacerbations**

---

*a* asthmatic features/features suggesting steroid responsiveness in this context include any previous secure diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time (at least 400ml) or substantial diurnal variation in peak expiratory flow (at least 20%).

*b* be aware of an increased risk of side effects (including pneumonia) in people who take ICS.

*c* Document in clinical records the reason for continuing ICS treatment.

d roflumilast may be an option as per NICE TA461 following specialist initiation and 3 months stabilisation.

Local expert opinion suggests a plasma eosinophil >0.3 x 10⁹/l is suggestive of asthmatic features.

*NICE recommends for patients using long-acting bronchodilators outside of the current recommendations and whose symptoms are under control, have the option to continue treatment until both, they and their clinician/healthcare professional agree it is appropriate to change.*

COPD Management
Updated August 2019 Review: July 2022
Page 8 of 20
Key messages for prescribers

Is the treatment working?
1. Has your treatment made a difference to you?
2. Is your breathing easier?
3. Is the inhaler device appropriate for the patient?

If there is no benefit from a new treatment – it should be stopped after an adequate trial period.
If the treatment is not working after checking adherence, compliance and inhaler technique - Review the diagnosis.

The effectiveness of bronchodilator therapy should not be assessed by lung function alone but should include a variety of other measures such as improvement in symptoms, activities of daily living, exercise capacity, and rapidity of symptom relief.

COPD assessment test (CAT)
Use COPD assessment tool (CAT) to assess the clinical response at baseline and when changing treatment.

Frequent exacerbators
An exacerbation is a sustained worsening of the patient’s symptoms from their usual stable state, which is beyond normal day-to-day variations, and is acute in onset.

Review “fundamentals of COPD care” which include:
• Check for co morbidities
  o E.g. anxiety/depression/
  o cardiac failure / IHD; Consider beta blockers in this case as they reduce death rates by 30% in COPD
• Vaccination status
• Referral for pulmonary rehabilitation
• CXR – to exclude other diagnosis e.g. lung cancer. If patients continues to exacerbate and the CXR is clear and no “red flag signs” refer to specialist as per COPD management pathway and NOT through the 2ww pathway.

Consider unusual organism:
• Check for Acid-Fast Bacillius (AFB), Pseudomonas

Consider wrong diagnosis?
• FEV1 / FVC <70%
• Bronchiectasis
• Cardiac failure
• CXR – to exclude other diagnosis e.g. lung cancer

COPD is a progressive disease with usual decline 40ml/year.
Inhaled therapies

1. **SABA or SAMA** (see appendix 4 for treatment options)
   Short acting bronchodilators may be used when required as the initial empirical treatment to relieve breathlessness and exercise limitation.

2. **LABA + LAMA combinations** (see appendix 4 for treatment options)
   The evidence shows that, compared with other dual therapy combinations and with monotherapy, the combinations LABA/LAMA:
   - provides the greatest benefit to overall quality of life
   - is better than other inhaled treatments for many individual outcomes (such as reducing the risk of moderate to severe exacerbations)
   - is the most cost-effective option
   (NICE NG115)

   NICE do not recommend a particular LAMA because they were not convinced that the evidence showed meaningful difference in effectiveness between the drugs in the class. There is no difference in cost for the current four available LABA/LAMA combinations, therefore choice between LABA/LAMA combination inhaler should be based on patient ability to tolerate and use the inhaler device.

   **Note** – tiotropium and glycopyrronium are associated with raised plasma concentrations with reduced renal function. Manufacturers advise use only if the potential benefits outweigh the risks. See SPC for tiotropium and glycopyrronium for further details.

3. **LABA + ICS combinations** (see appendix 4 for treatment options)
   Most trials specifically excluded people with COPD and asthma, so there was no direct evidence for this group. NICE recommended LABA/ICS based on their clinical experience and knowledge of the likely benefit of ICS in certain specific COPD phenotypes.

   NICE recommends not using oral corticosteroid reversibility tests to identify patients who should be prescribed inhaled corticosteroids, because it does not predict a response to inhaled corticosteroid therapy.

   Prescribers are reminded to be vigilant of potential adverse effects with ICS, these include:
   - Pneumonia
   - Anxiety
   - Sleep disorders
   - Behavioural changes, including psychomotor hyperactivity and irritability (predominantly in children)
   - Depression,
   - Aggression

   Long-term use with ICS is associated with a significant risk of pneumonia and systematic side-effects. Patients should be informed of the potential risks with ICS. (See appendix 1 for further details regarding side effects with ICS)
4. **LABA + LAMA + ICS** (see appendix 4 for treatment options)

There is stronger evidence from a greater number of studies that triple therapy benefits people taking LABA/ICS, compared with people taking LABA/LAMA.

For people currently taking LABA/ICS, the evidence showed that LABA/LAMA/ICS reduced the rate of severe exacerbations, improved FEV1 and did not increase the risk of pneumonia or other serious adverse effects.

For people currently taking LABA/LAMA, the evidence showed that LABA/LAMA/ICS reduced the rate of serious exacerbations and provides some quality of life improvement. However these improvements were smaller than the ones for people who are taking LABA/ICS before they started triple therapy. In addition, people who switched from LABA/LAMA to triple therapy were more likely to get pneumonia.

Conduct a clinical review before commencing triple inhaled therapy to ensure that all non-pharmacological COPD interventions have been optimised and that acute episodes of worsening symptoms are caused by COPD exacerbations and not by other physical or mental health conditions.

**NICE recommend for patients currently using**

- **LABA/ICS offer triple inhaled therapy to patients with asthmatic features if:**
  - their day-to-day symptoms continue to adversely impact their quality of life or
  - they have a severe exacerbation (requiring hospitalisation) or
  - they have 2 moderate exacerbations within a year.

- **LABA/LAMA consider triple inhaled therapy to patients with no asthmatic features if:**
  - They have severe exacerbation (requiring hospitalisation) or
  - They have 2 moderate exacerbations within a year

- **LABA/LAMA and whose day-to-day symptoms adversely impact their quality of life**
  - Consider a clinical review of breathless patients before moving to triple therapy
  - Consider a trial of triple therapy with caution, lasting for 3 months only
  - After 3 months, *conduct a clinical review, and if symptoms have not improved, stop LABA/LAMA/ICS and switch back to LABA/LAMA*
  - If symptoms have improved, continue with LABA/LAMA/ICS

Document the reason for continuing ICS use in clinical records and review at least annually.

**Choice of drugs/inhalers**

**NICE recommend the choice of drugs and inhalers should be based on:**

- how much the drug/inhaler improves symptoms
- the patients preference and ability to use the inhaler
- the drug’s potential to reduce exacerbations
- side effects
- cost

Consider stepping down treatment with an ICS - see local guidance for further details.

**Other therapies**

**Roflumilast (Brown- specialist initiation)**

Roflumilast is a phosphodiesterase type-4 inhibitor with anti-inflammatory properties. It is used as an add-on to bronchodilator therapy in adults with severe COPD with chronic bronchitis as per NICE TA461 if: *(Treatment is initiated by consultants in respiratory medicine)*

- the disease is severe, defined as FEV1 after a bronchodilator <50% of predicted normal, and
- the person has had ≥2 exacerbations in the previous 12 months despite triple inhaled therapy

Ongoing GP prescribing and care of patients on roflumilast should only be considered if patient is stable and free from adverse reactions, **after a minimum of 3 months roflumilast treatment under the Respiratory Specialist.**
Clinic letter from specialist should highlight:
- Assessment of any potential adverse effects including weight loss and psychiatric symptoms
- Response to treatment & reason for continuation of treatment

On-going management by GPs

<table>
<thead>
<tr>
<th>Body weight</th>
<th>Stop treatment and refer to specialist if unexplained and clinically concerning weight loss occurs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatric symptoms</td>
<td>Stop if new or worsening symptoms are experienced and refer to specialist</td>
</tr>
<tr>
<td>On-going benefits</td>
<td>Monitor exacerbations/clinical well-being/persistent intolerance</td>
</tr>
</tbody>
</table>

Inform specialist if patient:
- Develops any adverse effects related to treatment
- Is not responding to treatment
- Declines further treatment or discontinues treatment for other reasons.

Oral corticosteroids

Long-term oral corticosteroid therapy in COPD is not normally recommended. However some patients with advanced COPD may need long-term oral corticosteroids on specialist recommendation, when these cannot be withdrawn following an exacerbation. In these circumstances the dose of oral corticosteroid should be kept as low as possible.

Osteoprotection

Patients on or commencing high dose corticosteroid long-term (≥7.5mg per day of prednisolone or its equivalent for 3 months or more) should be offered bone protection with bisphosphonate. Patients taking lower doses of oral corticosteroids long-term should be considered for risk fracture assessment. See osteoporosis guidance for details.

Oral prophylactic antibiotic therapy

The respiratory specialist will recommend prophylactic antibiotic therapy.

Treatment recommendation will include:

- **Azithromycin** (*usually 250 mg 3 times a week*) (off-label) for COPD patients if they:
  1. do not smoke **and**
  2. have optimised non-pharmacological management and inhaled therapies, relevant vaccinations and (if appropriate) have been referred for pulmonary rehabilitation **and**
  3. continue to have 1 or more of the following, particularly if they have significant daily sputum production:
     - frequent (typically 4 or more per year) exacerbations with sputum production
     - prolonged exacerbations with sputum production
     - exacerbations resulting in hospitalisation

Before offering prophylactic antibiotics the respiratory specialist will ensure that the patient has had:

- sputum culture and sensitivity (including tuberculosis culture), to identify other possible causes of persistent or recurrent infection that may need specific treatment (for example, antibiotic-resistant organisms, atypical mycobacteria or Pseudomonas aeruginosa)
- training in airway clearance techniques to optimise sputum clearance
- a CT scan of the thorax to rule out bronchiectasis and other lung pathologies

Before starting azithromycin, ensure the patient has had:

- an ECG to rule out prolonged QT interval and
- baseline liver function tests.
- Advise patients there is a small risk of hearing loss and tinnitus

**Respiratory specialist will review prophylactic azithromycin after the first 3 months, and then at least every 6 months.** Only continue treatment if the continued benefits outweigh the risks.
Theophylline
Offer only after inhaler therapy has been optimised. (See UKMI drug monitoring guidance for theophylline monitoring).

Mucolytics (e.g. carbofisteine)
Mucolytic drug therapy should be considered in patients with a chronic cough productive of sputum and continued if there is symptomatic improvement (for example, reduction in frequency of cough and sputum production).

Consider trial of
- **NACSYS (N acetylcysteine) 600mg OD** or
- **carbofisteine capsules /sachets 750mg TDS** for 6-8 weeks then 750mg BD if improvement in sputum production and reduction in viscosity.
  
  Stop if no improvement.

Do not routinely use mucolytic to prevent exacerbations in people with stable COPD. Mucolytic therapy should be stopped if there is no benefit after a 4 week trial.

Anxiety and depression
NICE recommends that healthcare professionals should be alert to the presence of anxiety and depression in people with COPD, and that if present, these should be managed appropriately. Anxiety and depression should be considered if patients:

- have severe breathlessness
- are hypoxic
- have been seen at or admitted to a hospital with an exacerbation of COPD.

Managing exacerbations
An exacerbation is a sustained worsening of the patient's symptoms from their usual stable state, which is beyond normal day-to-day variations, and is acute in onset. Commonly reported symptoms are worsening breathlessness, cough, increased sputum production and change in sputum colour. Change in these symptoms often necessitates a change in medication.

NICE recommends *patients who have had an exacerbation of COPD* are provided with individualised exacerbation action plan, for early recognition of future exacerbations, management strategies (including appropriate provision of antibiotics and corticosteroids for self-treatment at home) and a named contact. (Contact the ImpACT or Community Respiratory team for advice).

Offer patients a short course of oral corticosteroids and a short course of oral antibiotics to keep at home to respond to an exacerbation if:

1. they have had an exacerbation within the last year, and remain at risk of exacerbations
2. they understand and are confident about when and how to take these medicines, and the associated benefits and harm.
3. Their use can be monitored and supported and there is a mechanism within primary care to identify those using >3 rescue packs per year. These patients should be reviewed.

Medication requirements for an exacerbation -

4. increase bronchodilator therapy to control symptoms
5. short course of oral **prednisolone 30mg daily 5 days**, if significant increase in breathlessness which interferes with daily activities
6. short course of **oral antibiotics**. See NICE NG114 on antimicrobial prescribing for acute exacerbations of COPD for further details of antibiotics.
Appendix 1: Inhaled corticosteroids

Local side effects

<table>
<thead>
<tr>
<th>Local side effects of inhaled corticosteroids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral candidiasis</td>
</tr>
<tr>
<td>Cough at time of inhalation</td>
</tr>
<tr>
<td>Hoarse voice</td>
</tr>
<tr>
<td>Dysphonia (disorder of the voice)</td>
</tr>
</tbody>
</table>

Cough is a local irritant effect and can usually be overcome by a change in the delivery device. For instance, when using metered dose inhaler (MDI), the addition of a large volume spacer will reduce the cough.

Oral candidiasis is dose-related and can be prevented by gargling, washing and spitting out after using the inhaler.

Hoarse voice and dysphonia are caused by the inhaled steroid being deposited on the vocal chords. These effects tend to be worse with dry powder inhaler than MDIs, where the effect can be decreased by using a large volume spacer. Hoarse voice and dysphonia are dose-related and are not usually a problem at low doses (except in those who use their voice professionally such as actors or singers).

Systemic side effects

<table>
<thead>
<tr>
<th>Potential systemic side effects of inhaled corticosteroids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenocortical suppression</td>
</tr>
<tr>
<td>Increased osteoporosis and bone fractures</td>
</tr>
<tr>
<td>Skin thinning and purpura</td>
</tr>
<tr>
<td>Weight gain</td>
</tr>
<tr>
<td>Cataracts</td>
</tr>
<tr>
<td>Glaucoma</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Increased pulmonary infections (pneumonia)</td>
</tr>
<tr>
<td>Growth retardation in children</td>
</tr>
</tbody>
</table>

Be aware of the potential risk of developing side-effects (including non-fatal pneumonia) in people with COPD treated with high of inhaled corticosteroid dose (particularly with 2000mcg beclometasone or equivalent dose) and discuss these with the patient.

Appendix 2: Spirometry

Spirometry is essential for making a correct diagnosis and determining the severity of COPD in conjunction with a detailed history and examination and should never be used solely in determining diagnosis. Spirometry is a reliable and effective tool if used correctly. The spirometer should be accurate, reliable and produce a copy of the graph with a volume/time plot. It should also include the following readings: Slow vital capacity (VC), Forced vital capacity (FVC), Forced expiratory capacity in one second (FEV1) and FEV1/FVC ratio (i.e <0.7). This is mandatory to meet specifications within the COPD guidelines for the management of the disease.

Other aspects which need to be taken into consideration are user friendliness and portability. You may also wish to consider a memory facility to store traces. Many electronic spirometers also display a flow volume curve. You do not need this information to calculate FEV1 and FVC values. However as you become more experienced you may want to have this facility.
Training
Training is important for health professionals responsible for performing spirometry. At least one member of staff from each practice should attend an accredited course which includes professional tuition on the practical application of spirometry and the correct interpretation of the results. Health care professionals who perform spirometry should have completed an approved competency based training course in spirometry and will be expected to keep their skills up to date.

Training courses available are as follows:

- Association for Respiratory Technology and Physiology (ARTP) - [www.artp.org.uk](http://www.artp.org.uk).
- Two day certificate courses on COPD and Spirometry
- Education for Health - The Athenaeum, 10 Church Street, Warwick CV34 4AB [www.educationforhealth.org.uk](http://www.educationforhealth.org.uk). Tel: 01926 493313 Fax: 01923 493224
- A range of one day workshops to identify learning needs and four to six month distance learning degree course. Spirometry workshop for HCAs.
- Respiratory Education UK - [www.respiratoryeduk.com](http://www.respiratoryeduk.com).
- One day workshops and 2 day diploma courses

The following organisations provide training in the use of spirometers:

ARTP/BTS certificate in spirometry The ARTP/BTS Consortium, c/o Dr SL Hill, Honorary Chairman ARTP/BTS Liaison Committee, Lung investigation Unit, The Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH. Telephone 0121 607 8339 Fax 0121 627 2012

Education for Health, The Athenaeum, 10 Church Street, Warwick CV34 4AB Tel: 01926 493313 Fax: 01926 493224

North Nottingham Respiratory Education Centre, The Kings Mill Centre, Mansfield Road, Sutton-in-Ashfield, Nottinghamshire NG17 4JL Tel: 01623 559568 Fax: 01623 556251

Respiratory Education UK, University Hospital Aintree, Lower Lane, Liverpool L9 7AL Tel: 0151 529 2598 Fax: 0151 529 3943

For further advice locally contact:
- North Derbyshire - Community Respiratory Team at Walton Hospital, Chesterfield on 01246 253 067

There is a [National Register of certified professionals and operators](http://www.derbyhospitals.nhs.uk/about/depts/respiratory/impact/information-for-primary-care/) for all healthcare professionals who have completed the training

Appendix 3: Oxygen therapy
Oxygen therapy should only be given to patients who have proven hypoxaemia (SaO₂ <92%, PaO₂ <7.3 kPa).

Record oxygen saturation on all patients with moderate to severe COPD.

Long Term Oxygen Therapy (LTOT)
If oxygen saturation ≤ 92% on 2 occasions (2-3 weeks apart), refer to oxygen assessment service for LTOT assessment. Further information on LTOT can be found in local [Oxygen guidance](http://www.derbyhospitals.nhs.uk/about/depts/respiratory/impact/information-for-primary-care/).
### Appendix 4: Cost comparison (Doses given do not imply therapeutic equivalence)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brand name</th>
<th>Device</th>
<th>Traffic light classification</th>
<th>Daily dose range</th>
<th>30 day cost</th>
<th>Annual cost</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LABA Inhalers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol DPI 12mcg</td>
<td>Easyhaler 12mcg</td>
<td>DPI</td>
<td><strong>GREEN</strong> 1&lt;sup&gt;st&lt;/sup&gt; line LABA</td>
<td>12mcg bd</td>
<td>£23.75 (120 dose)</td>
<td>£143</td>
</tr>
<tr>
<td>Formoterol MDI 12mcg</td>
<td>Atimos 12mcg</td>
<td>MDI</td>
<td><strong>GREEN</strong></td>
<td>12mcg bd</td>
<td>£30.06 (100 dose)</td>
<td>£216</td>
</tr>
<tr>
<td>Formoterol turbohaler 12mcg</td>
<td>Oxis 12mcg</td>
<td>DPI</td>
<td><strong>GREEN</strong></td>
<td>12mcg od - bd</td>
<td>£24.80 (60 dose)</td>
<td>£298</td>
</tr>
<tr>
<td>Salmeterol accuhaler 50mcg</td>
<td>Serevent 50 accuhaler</td>
<td>DPI</td>
<td><strong>GREEN</strong></td>
<td>50mcg bd</td>
<td>£35.11 (60 dose)</td>
<td>£421</td>
</tr>
<tr>
<td>Salmeterol MDI 25mcg</td>
<td>Soltei* MDI 25mcg</td>
<td>MDI</td>
<td><strong>GREEN</strong></td>
<td>50mcg bd</td>
<td>£19.95 (120 dose)</td>
<td>£239</td>
</tr>
<tr>
<td>Indacaterol 150mcg</td>
<td>Onbrez breezhaler</td>
<td>DPI Breath actuated</td>
<td>BROWN</td>
<td>150mcg od</td>
<td>£32.19 (30 dose)</td>
<td>£386</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td>-------</td>
<td>-----------</td>
<td>------------------</td>
<td>------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>300mcg od</td>
<td>£32.19 (30 dose)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>£386</td>
<td></td>
</tr>
<tr>
<td>Olodaterol respimat 2.5mcg</td>
<td>Striverdi respimat</td>
<td>Multi-dose solution for inhalation</td>
<td>BLACK</td>
<td>5mcg (2 puffs) od</td>
<td>£26.35 (60 dose)</td>
<td>£316</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAMA inhalers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiotropium Respimat 2.5mcg</td>
<td>Spiriva Respimat</td>
<td>Multi-dose solution for inhalation</td>
<td>GREEN 1st line LAMA</td>
<td>5mcg (2 puffs) od</td>
<td>£23.00 (60 dose)</td>
<td>£276</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiotropium Braltus</td>
<td>Braltus 10mcg</td>
<td>DPI Breath actuated</td>
<td>GREEN alternative 1st line LAMA</td>
<td>10mcg od</td>
<td>£25.80 (30 dose) (Zonda haler)</td>
<td>£310</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glycopyrronium 44mcg</td>
<td>Seebri Breezhaler &amp; caps</td>
<td>DPI Breath actuated</td>
<td>BROWN</td>
<td>1 inhalation od</td>
<td>£27.50 (30 dose)</td>
<td>£330</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aclidinium 322mcg</td>
<td>Eklira Genuair</td>
<td>DPI Breath actuated</td>
<td>BROWN</td>
<td>1 inhalation bd</td>
<td>£32.50 (60 dose)</td>
<td>£390</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Umeclidinium 55mcg</td>
<td>Incruse Ellipta</td>
<td>DPI Breath actuated</td>
<td>BROWN</td>
<td>55mcg od</td>
<td>£27.50 (30 dose)</td>
<td>£330</td>
</tr>
</tbody>
</table>
### LABA/LAMA combination inhaler (choice after 1st line should be driven by patient choice and device acceptability)

<table>
<thead>
<tr>
<th>Drug 1</th>
<th>Drug 2</th>
<th>Device</th>
<th>Device Type</th>
<th>Dose</th>
<th>Cost per dose</th>
<th>Cost per 60 dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indacaterol 110mcg</td>
<td>Glycopyrronium 50mcg</td>
<td>Ultibro Breezhaler and caps</td>
<td>DPI Breath actuated</td>
<td>GREEN</td>
<td>1 inhalation od</td>
<td>£32.50 (30 dose) £390</td>
</tr>
<tr>
<td>Formoterol 12mcg</td>
<td>aclidinium 340mcg</td>
<td>Duaklir Genuair</td>
<td>DPI Breath actuated</td>
<td>GREEN</td>
<td>1 inhalation bd</td>
<td>£32.50 (60 dose) £390</td>
</tr>
<tr>
<td>Vilanterol 22mcg</td>
<td>Umeclidinium 55mcg</td>
<td>Anoro Ellipta</td>
<td>DPI Breath actuated</td>
<td>GREEN</td>
<td>1 inhalation od</td>
<td>£32.50 (30 dose) £390</td>
</tr>
<tr>
<td>Olodaterol 2.5mcg</td>
<td>Tiotropium 2.5 mcg</td>
<td>Spiolto Respimat</td>
<td>Multi-dose solution for inhalation.</td>
<td>GREEN</td>
<td>2 inhalations od</td>
<td>£32.50 (60 dose) £390</td>
</tr>
</tbody>
</table>

### LABA/ICS Combination inhalers (ICS should only be used for patients with asthmatic features or features suggesting steroid responsiveness)

<table>
<thead>
<tr>
<th>Drug 1</th>
<th>Drug 2</th>
<th>Device</th>
<th>Device Type</th>
<th>Dose</th>
<th>Cost per dose</th>
<th>Cost per 60 dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budesonide 200mcg</td>
<td>Formoterol 6mcg</td>
<td>Fobumix 160/4.5</td>
<td>DPI Breath actuated</td>
<td>GREEN</td>
<td>2 puffs bd</td>
<td>£21.50 (120 dose) £258</td>
</tr>
<tr>
<td>Budesonide 400mcg</td>
<td>Formoterol 12mcg</td>
<td>Fobumix 320/9</td>
<td>DPI Breath actuated</td>
<td>GREEN</td>
<td>1 puff bd</td>
<td>£21.50 (60 dose) £258</td>
</tr>
<tr>
<td>Brand Name</td>
<td>Combinations</td>
<td>Packaging</td>
<td>Colour</td>
<td>Dose</td>
<td>Cost</td>
<td>Notes</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------</td>
<td>--------</td>
<td>----------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Beclomethasone 100mcg /formoterol 6mcg</strong></td>
<td>Fostair 100/6 (MDI)</td>
<td>MDI</td>
<td>GREEN 1st line MDI</td>
<td>2 puffs bd</td>
<td>£29.32 (120 dose)</td>
<td>£352</td>
</tr>
<tr>
<td><strong>Budesonide 200mcg /formoterol 6 mcg</strong></td>
<td>Symbicort 200/6 MDI</td>
<td>MDI</td>
<td>GREEN</td>
<td>2 puffs bd</td>
<td>£28.00 (120 dose)</td>
<td>£336</td>
</tr>
<tr>
<td><strong>Budesonide 200mcg /formoterol 6 mcg</strong></td>
<td>Symbicort 200/6 DPI Breath actuated</td>
<td>DPI</td>
<td>GREEN</td>
<td>2 puffs bd</td>
<td>£28.00 (120 dose)</td>
<td>£336</td>
</tr>
<tr>
<td><strong>Budesonide 400mcg /formoterol 12 mcg</strong></td>
<td>Symbicort 400/12 DPI Breath actuated</td>
<td>DPI</td>
<td>GREEN</td>
<td>1 puffs bd</td>
<td>£28.00 (60 dose)</td>
<td>£336</td>
</tr>
<tr>
<td><strong>Budesonide 200mcg /formoterol 6mcg</strong></td>
<td>DuoResp spiromax 160/4.5 DPI Breath actuated</td>
<td>DPI</td>
<td>GREEN</td>
<td>2 puff bd</td>
<td>£27.97 (120 dose)</td>
<td>£336</td>
</tr>
<tr>
<td><strong>Budesonide 400mcg /formoterol 12mcg</strong></td>
<td>DuoResp spiromax 320/9 DPI Breath actuated</td>
<td>DPI</td>
<td>GREEN</td>
<td>1 puff bd</td>
<td>£27.97 (60 dose)</td>
<td>£336</td>
</tr>
</tbody>
</table>
### COPD Management

Updated: August 2019  
Review date: July 2022

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Brand</th>
<th>Type</th>
<th>Color</th>
<th>Route</th>
<th>Dosing</th>
<th>Cost (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beclomethasone 100mcg/formenterol 6mcg</td>
<td>Fostair NEXThaler 100/6 (DPI)</td>
<td>DPI Breath actuated</td>
<td>GREEN</td>
<td>2 puffs bd</td>
<td>£29.32 (120 dose)</td>
<td>£352</td>
</tr>
<tr>
<td>Fluticasone 500mcg/salmeterol 50mcg</td>
<td>Fusacomb easyhaler 50/500mcg</td>
<td>DPI Breath actuated</td>
<td>GREEN</td>
<td>1 puff bd</td>
<td>£26.99 (60 dose)</td>
<td>£324</td>
</tr>
<tr>
<td>Fluticasone Furoate 92mcg/Vilanterol 22mcg</td>
<td>Relvar Ellipta</td>
<td>DPI Breath actuated</td>
<td>BROWN</td>
<td>1 inhalation od</td>
<td>£22.00 (30 dose)</td>
<td>£264</td>
</tr>
</tbody>
</table>

**LABA/LAMA/ICS combination inhaler**

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Brand</th>
<th>Type</th>
<th>Color</th>
<th>Route</th>
<th>Dosing</th>
<th>Cost (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beclometasone 87mcg/Formoterol 5mcg/glycopyrronium 9 mcg</td>
<td>Trimbow</td>
<td>MDI (Extrafine)</td>
<td>BROWN</td>
<td>2 inhalations bd</td>
<td>£44.50 (120 dose)</td>
<td>£534</td>
</tr>
<tr>
<td>Fluticasone furoate 92mcg/Vilanterol 22 mcg/Umeclidinium 65 mcg</td>
<td>Trelegy Ellipta</td>
<td>DPI Breath actuated</td>
<td>BROWN</td>
<td>1 inhalations od</td>
<td>£44.50 (30 dose)</td>
<td>£534</td>
</tr>
</tbody>
</table>

*(All cost obtained from MIMS online August 2019. Prescribe combination inhaler by brand)*

* Soltel CFC-free Inhaler 25 micrograms contains soya lecithin and is contraindicated in patients who have peanut or soya allergies. If the patient has a soya and nut allergy then prescribe salmeterol by brand name – severent.